drugset / Trial / NCT01015404

A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

NCT01015404 ↗

Phase 3 Completed 25 enrolled Kaken Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate the safety in using Trafermin (recombinant human basic fibroblast growth factor) with periodontal surgery.

Timeline

Start
2009-11
Primary completion
2010-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Trafermin Protein / enzyme biologic 0.2 ml —
Subject Trafermin Protein / enzyme biologic 0.3 % —
Subject Trafermin Protein / enzyme biologic 0.6 ml —

Indications